Jason C. Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS*

In his June Editor-in-Chief letter, Dr. Jason Gallagher explores the influence of preprints amid the COVID-19 pandemic.

The health system’s response could be used as a teaching model for addressing future infectious disease threats.

COVID-19 does not present our first pandemic, nor will it be our last. What should we take note of?

Just as influenza season started ramping up in the Northern Hemisphere, news hit the wire that Sanofi had secured over-the-counter rights for oseltamivir (Tamiflu).

Something novel in infectious diseases practice has occurred and, like many big changes, it is not without controversy.

In the October Editor-in-Chief letter, Dr. Jason Gallagher writes about the role clinicians play in helping patients understand antibiotic resistance.

In the August Editor-in-Chief's Letter, Dr. Jason Gallagher discusses how we can improve outpatient antimicrobial stewardship.

The June Editor-in-Chief letter by Dr. Jason Gallagher tackles the story of Achaogen and what its bankruptcy means for antibiotic development.

Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, reacts to news of the London patient, the second person cured of HIV infection.

Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, kicks off his second year as editor-in-chief by welcoming 6 industry experts on as section editors.

Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, reflects on 2018 and his first full year as Contagion®'s editor-in-chief.